CJC-1295 without DAC is just GRF 1-29 with two amino acid substitutions — the same molecule as Sermorelin. CJC-1295 WITH DAC (Drug Affinity Complex) adds a albumin-binding moiety that dramatically extends its half-life. This extension is real. The "two weeks of elevated GH" claim based on it is not.

The Two Versions (This Is Not Widely Understood)

There are two CJC-1295 products on the market, and they have meaningfully different pharmacokinetics. Peptide clinics often present them interchangeably, which is misleading.

CJC-1295 (without DAC): The original modified GRF 1-29. The modifications improve stability and increase half-life compared to native GHRH, but it's still a peptide with a relatively short half-life — approximately 30-45 minutes in humans based on pharmacokinetic studies. This is essentially the same compound as Sermorelin, with comparable duration of action. Anyone claiming CJC-1295 (non-DAC) has a "two-week" effect either doesn't understand the chemistry or is misrepresenting the product.

CJC-1295 DAC (also called CJC-1295 with albumin): The addition of the DAC moiety (a maleimido chain that covalently binds to albumin) extends the effective half-life substantially — studies suggest 8-10 days in humans. This is the version that can be dosed once or twice weekly rather than daily. The DAC version is pharmacologically distinct from the non-DAC version in terms of dosing frequency and possibly in GH elevation profile.

Most peptide clinics sell the DAC version as standard, but the two versions are frequently conflated in marketing, which makes it hard to evaluate claims about either.

What "Half-Life Extension" Actually Means for GH Elevation

The longer half-life of CJC-1295 DAC means the compound remains in circulation longer, which produces sustained stimulation of the GHRH receptor. The marketing translates this into "2 weeks of elevated GH from one injection" — and this is where the pharmacokinetic-to-pharmacodynamic extrapolation breaks down.

GH secretion is pulsatile. It follows a circadian pattern with the largest pulses occurring during deep sleep. The GHRH receptor responds to stimulation with a refractory period — continuous stimulation produces a weaker GH response over time as the receptor desensitizes. So a compound that remains in the body for 2 weeks does not produce 2 weeks of elevated GH pulses. It produces an initial surge, followed by receptor downregulation, followed by a blunted response to subsequent stimulation.

The "two weeks of elevated GH" claim got a 5/10 — the pharmacokinetic half-life extension is real, but the translation to sustained GH elevation over that period ignores receptor pharmacology.

The "600% HGH Increase" Claim

The CJC-1295 + Ipamorelin stack is frequently marketed as boosting HGH by "600%" or similar figures. These numbers come from combining IGF-1 increases from CJC-1295 trials with GH secretagogue acute response data, then multiplying the two effects. This is not how pharmacology works.

In practice: CJC-1295 DAC increases baseline IGF-1 levels in a measurable range (studies suggest 20-40% above baseline over 2-4 weeks of dosing). Ipamorelin produces an acute GH pulse when administered (typically 2-5x baseline). The "600%" figure is the maximum observed GH spike multiplied by the IGF-1 elevation, applied to a single time point, and presented as the sustained effect of the protocol. The actual sustained effect is lower, the effect over a full protocol is variable, and individual responses to GH secretagogues differ substantially based on age, sex, body fat, and baseline GH status.

The CJC-1295/Ipamorelin stack claim is not necessarily wrong that these compounds increase GH — they do. But the quantification is a marketing number, not a research finding.

The IGF-1 Elevation Problem

IGF-1 (Insulin-like Growth Factor 1) is the primary mediator of GH's effects on tissue growth and metabolism. CJC-1295 DAC reliably elevates IGF-1 in clinical trials. This is the mechanism by which its effects — whatever they are — would be mediated.

IGF-1 elevation is a double-edged sword. Above a certain threshold, elevated IGF-1 is associated with increased cancer risk in observational studies (though the relationship is complex and probably U-shaped, not linear). There is no long-term study of what sustained IGF-1 elevation at the upper end of the "therapeutic range" does to cancer risk in adults without GH deficiency. The absence of this data is a significant unknown that the peptide marketing complex prefers not to discuss.

The Honest Pharmacokinetic Summary

  • CJC-1295 non-DAC: ~30-45 min half-life. Comparable to Sermorelin. Daily dosing required. IGF-1 elevation modest and variable.
  • CJC-1295 DAC: ~8-10 day half-life. Sustained GHRH receptor stimulation. Weekly or twice-weekly dosing. IGF-1 elevation measurable, clinical significance uncertain. No long-term safety data at elevated IGF-1 levels.

The half-life extension is real. The clinical outcome translation — sustained GH elevation and meaningful body composition or anti-aging effects — is not established by human trials.

Bottom Line

If you're going to use CJC-1295, the DAC version has a legitimate pharmacokinetic advantage in terms of dosing frequency. But "compounding pharmacy sells you something with a longer half-life" is not the same as "this compound produces clinically meaningful outcomes in healthy adults." The two-week GH elevation claim and the 600% boost claim are both marketing extrapolations from pharmacokinetic data that don't translate cleanly to pharmacodynamic outcomes. IGF-1 elevation is real, measurable, and its long-term safety profile is unknown. Before running any GHRH protocol, ask what you're actually trying to achieve and what evidence supports achieving it.